Clinical Trial Update: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). [Phase 3]

View source ↗

Summary

This clinical trial update reports results from a Phase 3 study comparing two dosing regimens of glatiramer acetate for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2010-05-14